Delivery Order 36F79719D0108-36C24924F0077
Award Date 2/15/24
Potential Completion Date 3/15/24
Potential Value $63K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a firm fixed-price delivery order to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., to provide the specialty medication GALAFOLD 123 MG. This delivery order, valued at $21,089.47, is being issued under the General Services Administration's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract. Amicus Therapeutics US, LLC has previously been awarded multiple delivery orders...
- The Department of Veterans Affairs Veterans Health Administration has awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of the biopharmaceutical company Amicus Therapeutics, Inc., to provide the specialty medication Galafold (migalastat) under the GSA's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The potential value of this delivery order is $63,268.41, and it is intended to fulfill the VA's pharmaceutical requirements to support healthcare...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on August 6, 2025, with a ceiling value of $21,891.21. This firm fixed-price delivery order, which is expected to be completed by August 8, 2025, represents a task order under the parent Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The award was made without a set-aside designation and...
- This is a firm fixed price delivery order contract awarded by the Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the emergency procurement of migalastat (Galafold), a drug used to treat Fabry disease, a rare genetic disorder. The delivery order, valued at $21,089.47, was placed against Amicus Therapeutics US, LLC's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract administered by the General...
- This is a firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is valued at $197,020.89 and has a completion date of May 31, 2025. The contract is for the delivery of the pharmaceutical product Galafold 123mg, an enzyme replacement therapy used to treat Fabry disease. Amicus Therapeutics US, LLC holds a Federal Supply Schedule (FSS) contract (36F79724D0185) with...
- The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., for the specialty medication Galafold (migalastat) to treat Fabry disease. The $21,089.47 award was placed against Amicus Therapeutics, Inc.'s Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract with the General Services Administration, which provides a mechanism for federal agencies to procure...
- This is a $21,891.21 firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the delivery of GALAFOLD 123 MG, an enzyme replacement therapy used to treat Fabry disease, to the VA's Veterans Integrated Service Network 5 (VISN 5) in Philadelphia, Pennsylvania. The contract was awarded on September 24, 2025 and has a completion date of September 29, 2025. The...
- This is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the supply of 3 bottles of Galafold, an enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The contract, valued at $65,673.63, is part of a larger Federal Supply Schedule (FSS) contract (36F79724D0185) between the VA and Amicus Therapeutics US, LLC, which is valid through...
- This is a firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a pharmaceutical company focused on rare genetic diseases. The contract is for the supply of the drug Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. The contract, valued at $21,891.21, is a task order under the VA's Federal Supply Schedule (FSS) contract 36F79724D0185 for Pharmaceuticals and Drugs (FSS-61-IB), which has a total...
- This federal contract award was issued by the Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 5 (VISN 5), to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the delivery of Galafold 123 mg, an FDA-approved enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The contract is a delivery order under the General Services Administration's (GSA) Pharmaceuticals and Drugs (FSS-61-IB) Federal...